AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Cancer Education
Explore expert insights on the fundamentals of cancer, including how it develops, key risk factors, prevention strategies, and treatment options. This section also highlights cancer awareness months and related observance days and weeks. Commentaries from our network of oncology professionals shed light on critical issues that require greater attention across the cancer care and research continuum.
The Shifting Playbook for Relapsed Large B-Cell Lymphoma: From Transplant to CAR T and Beyond
By Krishna Rekha Moturi, MBBS
Second-line care for relapsed large B-cell lymphoma has moved decisively away from salvage chemotherapy and transplant toward CAR T-cell therapy for patients with early relapse.
The Shifting Playbook for Relapsed Large B-Cell Lymphoma: From Transplant to CAR T and Beyond
By Krishna Rekha Moturi, MBBS
Second-line care for relapsed large B-cell lymphoma has moved decisively away from salvage chemotherapy and transplant toward CAR T-cell therapy for patients with early relapse.
The Shifting Playbook for Relapsed Large B-Cell Lymphoma: From Transplant to CAR T and Beyond
By Krishna Rekha Moturi, MBBS
Second-line care for relapsed large B-cell lymphoma has moved decisively away from salvage chemotherapy and transplant toward CAR T-cell therapy for patients with early relapse.
Hormone Receptor-Positive Breast Cancer in 2026: ctDNA-Guided Switching and the Expanding Oral SERD Landscape
By Manpreet Kaur Chadha, MD
Care for hormone receptor-positive, HER2-negative advanced breast cancer is broadening well past the traditional aromatase inhibitor backbone.
Hormone Receptor-Positive Breast Cancer in 2026: ctDNA-Guided Switching and the Expanding Oral SERD Landscape
By Manpreet Kaur Chadha, MD
Care for hormone receptor-positive, HER2-negative advanced breast cancer is broadening well past the traditional aromatase inhibitor backbone.
Hormone Receptor-Positive Breast Cancer in 2026: ctDNA-Guided Switching and the Expanding Oral SERD Landscape
By Manpreet Kaur Chadha, MD
Care for hormone receptor-positive, HER2-negative advanced breast cancer is broadening well past the traditional aromatase inhibitor backbone.
Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow
By Arika Sandbach, PharmD, BCOP
Capivasertib, an oral AKT inhibitor for HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations, carries a labeled hyperglycemia risk requiring structured, front-loaded monitoring.
Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow
By Arika Sandbach, PharmD, BCOP
Capivasertib, an oral AKT inhibitor for HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations, carries a labeled hyperglycemia risk requiring structured, front-loaded monitoring.
Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow
By Arika Sandbach, PharmD, BCOP
Capivasertib, an oral AKT inhibitor for HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations, carries a labeled hyperglycemia risk requiring structured, front-loaded monitoring.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Hidden Dosing Trap in Antibody-Drug Conjugates: How Weight-Based Rounding Can Silently Double a Dose Increase
By Ian Ingram, PharmD, BCOP
A delayed neutropenia case reveals how UGT1A1 metabolizer status and weight-based dose rounding can silently double a sacituzumab dose error.
A Near-Complete Response to Immunotherapy Highlights an Overlooked Sun-Driven Sarcoma
By Athar Eysa, MD
Pleomorphic dermal sarcoma is a rare, ultraviolet-driven skin cancer that shares biology with better-known immunogenic tumors.
A Near-Complete Response to Immunotherapy Highlights an Overlooked Sun-Driven Sarcoma
By Athar Eysa, MD
Pleomorphic dermal sarcoma is a rare, ultraviolet-driven skin cancer that shares biology with better-known immunogenic tumors.
A Near-Complete Response to Immunotherapy Highlights an Overlooked Sun-Driven Sarcoma
By Athar Eysa, MD
Pleomorphic dermal sarcoma is a rare, ultraviolet-driven skin cancer that shares biology with better-known immunogenic tumors.
Peripheral T-Cell Lymphoma: Why "Not Otherwise Specified" Should Be a Last Resort, Not a Default
By Yumeng Zhang, MD
T-cell lymphomas account for roughly 10% of non-Hodgkin lymphoma in Western countries, and up to about 20% in parts of Asia, a genuine epidemiologic difference.
Peripheral T-Cell Lymphoma: Why "Not Otherwise Specified" Should Be a Last Resort, Not a Default
By Yumeng Zhang, MD
T-cell lymphomas account for roughly 10% of non-Hodgkin lymphoma in Western countries, and up to about 20% in parts of Asia, a genuine epidemiologic difference.
Peripheral T-Cell Lymphoma: Why "Not Otherwise Specified" Should Be a Last Resort, Not a Default
By Yumeng Zhang, MD
T-cell lymphomas account for roughly 10% of non-Hodgkin lymphoma in Western countries, and up to about 20% in parts of Asia, a genuine epidemiologic difference.
PD-L1 Alone Isn't Enough, and Neither Is TMB: What Would a Real Immunotherapy Biomarker Look Like?
By Robert Samstein, MD, PhD
Only a minority of patients meaningfully benefit from immunotherapy, and right now we largely rely on a single, binary metric (PD-L1) to try to select who that is.
PD-L1 Alone Isn't Enough, and Neither Is TMB: What Would a Real Immunotherapy Biomarker Look Like?
By Robert Samstein, MD, PhD
Only a minority of patients meaningfully benefit from immunotherapy, and right now we largely rely on a single, binary metric (PD-L1) to try to select who that is.
PD-L1 Alone Isn't Enough, and Neither Is TMB: What Would a Real Immunotherapy Biomarker Look Like?
By Robert Samstein, MD, PhD
Only a minority of patients meaningfully benefit from immunotherapy, and right now we largely rely on a single, binary metric (PD-L1) to try to select who that is.
Two Advances Are Reshaping Bladder Cancer Care Before and After Surgery
By Munveer Bhangoo, MD
For more than two decades, cisplatin-based chemotherapy followed by radical cystectomy has been the standard approach to muscle-invasive bladder cancer (MIBC)
Two Advances Are Reshaping Bladder Cancer Care Before and After Surgery
By Munveer Bhangoo, MD
For more than two decades, cisplatin-based chemotherapy followed by radical cystectomy has been the standard approach to muscle-invasive bladder cancer (MIBC)
Two Advances Are Reshaping Bladder Cancer Care Before and After Surgery
By Munveer Bhangoo, MD
For more than two decades, cisplatin-based chemotherapy followed by radical cystectomy has been the standard approach to muscle-invasive bladder cancer (MIBC)
A Rare Liver Cancer in a Young Woman Underscores the Need for More Options
By Erika Maestas, MD
Fibrolamellar hepatocellular carcinoma is a rare liver cancer that strikes young people without the usual liver disease risk factors, and it has no systemic therapy proven to extend survival.
A Rare Liver Cancer in a Young Woman Underscores the Need for More Options
By Erika Maestas, MD
Fibrolamellar hepatocellular carcinoma is a rare liver cancer that strikes young people without the usual liver disease risk factors, and it has no systemic therapy proven to extend survival.
A Rare Liver Cancer in a Young Woman Underscores the Need for More Options
By Erika Maestas, MD
Fibrolamellar hepatocellular carcinoma is a rare liver cancer that strikes young people without the usual liver disease risk factors, and it has no systemic therapy proven to extend survival.
ER-Positive Breast Cancer in 2026: New Oral Endocrine Agents and the Case for ctDNA-Guided Switching
By Natalie Chen, MD
Despite substantial treatment advances, roughly a quarter of patients with early-stage ER-positive breast cancer still develop recurrence within five years
ER-Positive Breast Cancer in 2026: New Oral Endocrine Agents and the Case for ctDNA-Guided Switching
By Natalie Chen, MD
Despite substantial treatment advances, roughly a quarter of patients with early-stage ER-positive breast cancer still develop recurrence within five years
ER-Positive Breast Cancer in 2026: New Oral Endocrine Agents and the Case for ctDNA-Guided Switching
By Natalie Chen, MD
Despite substantial treatment advances, roughly a quarter of patients with early-stage ER-positive breast cancer still develop recurrence within five years